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ABSTRACT
Purpose: To explore the post-treatment experiences and preferences for followup support of lymphoma survivors.
Methods: Two focus groups were conducted with 17 participants to explore
informational, psychological, emotional, social, practical and physical needs, 6-30
months post-treatment for lymphoma. Perceptions regarding a potential model of
survivorship care were also elicited.
Results: Thematic content analysis revealed five key themes: Information; Loss
and uncertainty; Family, support and post-treatment experience; Transition, connectivity
and normalcy, and Person-centred post-treatment care. Participants described a sense
of loss as they transitioned away from regular interaction with the hospital at the end of
treatment, but also talked about the need to find a “new normal”. Establishing posttreatment support structures that can provide individualised information, support,
reassurance and referrals to community and peer support were identified as a helpful
way to navigate the transition from patient to post-treatment survivor.
Conclusions: Participants in our study articulated a need for a flexible approach
to survivorship care, providing opportunities for individuals to access different types of
support at different times post-treatment. Specialist post-treatment nurse care
coordinators working across acute and community settings may offer one effective
model of post-treatment support for survivors of haematological malignancies.
KEYWORDS
Lymphoma; focus groups, survivorship; unmet needs
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INTRODUCTION
Lymphomas are complex, potentially life limiting haematological (blood)
malignancies that have a marked impact on quality of life and long-term health as a
consequence of the aggressive or chronic nature of the treatments required to manage
them (Carey et al., 2012). Lymphomas are immune-related cancers, broadly
categorised as non-Hodgkin or Hodgkin lymphoma, and can be indolent or aggressive
in nature (National Cancer Institute, 2016). Advances in treatment efficacy, including
haematopoietic stem cell transplants, bone marrow support with blood component
transfusions and white cell stimulation, along with advances in decreasing severity of
infection risk, remission rates have improved (Lichtman, 2008).
In Australia, the context for this study, the 2012 estimated age-standardised rates
(ASRs) of Hodgkin lymphoma incidence and mortality were 2.7 and 0.3 respectively
(Cancer Australia, 2017a). These figures compare favourably with the European Union
(EU-27) estimated ASRs of Hodgkin lymphoma incidence (2.3) and mortality (0.4) for
the same period (Ferlay et al., 2013). The estimated Australian ASRs of incidence and
mortality for Non-Hodgkin lymphoma were 19.1 and 5.4 respectively compared with EU27 estimated ASRs of 11.6 and 3.8 respectively (Cancer Australia, 2017b; Ferlay et al.,
2013)
Late and long-term side effects of treatment for lymphoma are common and can
include fatigue; nutritional and physical activity deficits; fertility, sexuality and
relationship concerns; and financial, employment and insurance issues (Allart et al.,
2013; Arden-Close et al., 2011; Hall et al., 2013b). As advances in remission and cure
rates improve, survivors are living longer with the consequences of their disease and
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treatment (Sant et al., 2014), and many experience unmet needs that impact long-term
health and wellbeing (Arden-Close et al., 2011). In a study of 53 long-term survivors of
leukaemia and lymphoma (Zebrack, 2000), issues such as fatigue (n=23, 42%),
remained an ongoing problem. The authors indicated fear of recurrence and financial
concerns were also predominant factors in long-term survivors (no figures given). In a
study of 437 haematology survivors in Australia and Canada, fatigue was identified as
the greatest unmet concern (n=76, 16%), with the Australian cohort only (n=268, 61%)
reporting a higher level of unmet financial concerns (n=39, 15%) (Hall et al., 2013a).
Survivors of haematological malignancies have been show to experience ongoing
issues up to a decade or more post-treatment completion (Ferrer et al., 2011). Severe
fatigue impacting functional capacity, emotional well-being and ability to return to work
(Ferrer et al., 2011; Kangas et al., 2008; Oerlemans et al., 2013), and persistent
cognitive impairment have been reported as debilitating long-term effects of treatment
(van der Poel et al., 2014).
There is limited evidence available to inform the development of patient-focused
haematology survivorship services in Australia. However, some evidence exists to
indicate patients’ preferences for post-treatment follow-up care. In a study of 66 cancer
survivors representing the major haematological diagnostic groups (non-Hodgkin
lymphoma 48%, Hodgkin lymphoma 12%, multiple myeloma 26%, leukaemia 14%),
help with managing the fear of recurrence (42%) and ongoing case management (33%)
were identified as unmet needs in the post-treatment period (Lobb et al., 2009). The
opportunity to discuss experiences with a health care professional at treatment
completion was identified as potentially helpful by 59% of participants. McGrath (2014)
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reported findings from a qualitative study of 50 haematology survivors that explored use
of routine telephone follow-up as a supportive care strategy. The sample represented
the haematologic diagnostic groups of multiple myeloma (n=15), lymphoma (n=14) and
leukaemia (n=17). Although telephone follow-up support was perceived by the majority
of participants as potentially beneficial, many individuals did not support the idea as
they wanted to ‘move on’ from cancer and would not have welcomed any contact.
Unlike more common malignancies such as breast and prostate cancer, evidence
to inform the development of optimal follow-up guidelines for haematological
survivorship care is lacking. This study set out to explore the experiences of and
preferences for post-treatment support in Australian survivors of lymphoma 6-30 months
post-treatment completion. For the purpose of the study, participants were deemed
‘lymphoma survivors’ if their haematologist had documented ongoing remission at least
six months from treatment completion as our intent was to better understand posttreatment support needs.

METHODS
Methodological Framework
We undertook a qualitative, descriptive study (Neergaard et al., 2009;
Sandelowski, 2000) utilising focus groups to explore and better understand the posttreatment experiences and support needs of lymphoma survivors. Focus groups allow
for collection of a broad range of information and insight when little is known or
understood about a topic (Neergaard et al., 2009; Sandelowski, 2000), while providing
peer support and normalisation of experiences that group participants may share.
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Excellent facilitation is important to ensure all participants have an opportunity to
contribute as they wish, avoiding dominance of one or two experiences (Tausch and
Menold, 2016). For the purpose of our study, a PhD prepared haematology clinical
psychologist experienced in conducting focus groups with vulnerable populations,
facilitated the digitally recorded focus groups and was supported by a specialist cancer
nurse who acted as scribe to support detail and accuracy of interpretation of the digitally
recorded focus group data.
The study was approved and undertaken in accordance with the ethical
standards guiding the Human Research Ethics Committees of the relevant study site
and university. Informed written consent was obtained from all participants prior to study
participation.

Sample and setting
The study was undertaken at a large tertiary hospital with a comprehensive
cancer centre in Western Australia. Between 1 July 2009 and 1 December 2013, 479
patients were referred to the hospital for treatment of lymphoma. Potentially eligible
study participants were identified through a manual search of the hospital cancer
registry patient records. Eligibility criteria included: i) aged over 25 years (in Australia
Youth Cancer Services provide specialist, age-appropriate treatment and support for
young cancer patients aged 15 – 25; ii)) currently residing in Western Australia; iii) fluent
in English; iv) completed treatment at least 6 months prior to study; and v) no cognitive
impairment (as indicated in the medical record or during recruitment process where
participants’ ability to understand the study details and provide consent was assessed).
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Exclusion criteria were patients who: i) had relapsed after first-line therapy; ii) were
receiving care or follow-up or had undertaken an allogeneic transplant at another
hospital; and iii) were undergoing work-up for autologous transplant. These exclusion
criteria ensured experiences from other hospital sites and continuing treatment
experiences did not influence the data collected.

Focus Groups
Two digitally recorded focus groups were carried out and data from each group
transcribed verbatim. The transcriptions were checked for accuracy by the facilitator and
support nurse, drawing on the notes taken during the groups and by listening to the
recordings. Digital recordings of interviews and transcribed interviews were saved in
password-protected files on a secure server.
A semi-structured interview guide was developed by the research team based on
previously reported study data and clinical experience. Interview questions allowed for
exploration of informational, psychological, emotional, social, practical, physical and
spiritual aspects of post-treatment support need. Participants were also asked to talk
about what they thought would have been or could be of help to them in the posttreatment period.

Data Analysis
The focus group transcript data were imported into NVivo to enable the
management of data, and the process of data analysis. Thematic content analysis
methodology was applied to explore and organise data into codes and themes (Braun
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and Clarke, 2006). Transcripts were initially coded by CB. Subsequently each transcript
was read independently by two other members of the study team (TM, KT). Thematic
content analysis is a widely used analytical approach to qualitative data where themes,
identified through coding, reflect key patterns within the textual data. This inductive
approach was regarded as the most appropriate for our data, allowing themes to
emerge from the content of the focus groups rather than considering data in response to
questions pre-constructed by the researchers (Sarantakos, 2013). Data saturation point
was reached following analysis of the two focus groups.

Rigour
Researchers (KT, CB and TM) met to discuss outcomes from the independent
coding process and agreed on emerging themes. Discrepancies were discussed until
consensus was reached. This allowed for development of a coding system that ensured
a strategy of reliability throughout the process (Morse, 2015). Rigour of data analysis
was ensured by applying the criteria of credibility, auditability and fittingness (Beck,
1993). Credibility was obtained through use of researchers to complete independent
coding thereby ensuring categories accurately captured issues being discussed.
Decisions related to allocation of discrete data elements to codes and fittingness of the
codes, were demonstrated through extensive use of quotes or extracts from the data.
Fittingness was further achieved by reflecting on the core concepts of unmet
survivorship needs as confirmed by the research team (van Manen, 1997).
Documentation of all steps in the analysis process, including opportunities for reflection
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on the codes and debriefing about the content of the transcription ensured a coherent
audit trail and therefore maintained auditability.

RESULTS
Participants
Of the 79 eligible lymphoma participants, 11 returned opt-out forms without
providing a reason for this decision. The remaining 68 participants were contacted to
further explain the study and provide focus group details. Of these 22 (32%) agreed to
participate in a focus group, however five people did not attend on the day. Reasons for
non-participation included: migrating overseas / interstate (n=2); recently relapsed or
other cancer (n=5); family bereavement (n=1); working fulltime (n=1); declined to
provide a reason when contacted by telephone (n=20); did not respond to voicemail
message (n=13); severe symptom burden (n=1); unable to arrange transport (n=1);
family objection (n=1); deceased (n=1).
The disease and demographic characteristics of the participants who did not take
part in a focus group were comparable with those who participated. The age range of
participants was 27 to 85 years with a mean age of 63.8 years (SD 14.5). The average
time since last treatment was 14.6 months (SD 8.2) with a range of 6-30 months (Table
1).
Table 1 Participant demographic information (N=17)
Demographic
Focus Group 1
Focus Group 2
variable

N=8

N=9

Male

5

4

Female

3

5

Gender
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Age
25-35

0

1

36-50

2

0

51-64

1

2

65-79

5

5

80+

0

1

Married

5

5

De Facto

2

1

Divorced

0

2

Single

1

1

NHL

7

9

HL

1

0

Married Status

Diagnosis

Time since treatment
completion
6-11 months

4

12-16 months

4

17-24 months

7

25-29 months

2

Themes
Five themes emerged from analysis and coding of data: Information; Loss and
uncertainty; Family, support and post-treatment experience; Transition, connectivity and
normalcy, and Person-centred post-treatment care.
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Information
Participants described difficulty in obtaining information from some members of
the health care team after treatment had finished, feeling that professionals sometimes
didn’t understand or pre-empt the type of information and support they required posttreatment:
“My GP doesn’t even really know that much about cancer, I think I’ve been teaching him …
but you could phone the Cancer Council and get quite a bit of information if you wanted
to…” F_46yo_NHL

Participants indicated that a generic list of services and written information describing
what to expect post-treatment would be helpful:
“An instruction sheet, so basically you've just had your last chemotherapy session one month
ago, you’ve done your test, you’re in remission, here’s what you need to do for the next 12
months” M_48yo_HL

Compounding the issue of information support was recognition that retention of
information given in preparation for end of treatment was challenging and that being
given important information at different times or repeatedly may be helpful:
“I don’t think anyone explains it all to us, is there a rule book? ‘After 3 months, you
should…’” M_ 48yo_HL
“I think about things in between visits … I have questions, so every three months I come
back” F_73yo_NHL

Loss and uncertainty
Post-treatment side effects were spoken about in terms of loss; a loss of strength
and physical function, a loss of control around nutrition and sustenance, a loss of
energy and interest, and a loss of concentration. Comments around what to expect
indicated most would have found it helpful to know how long side effects continue for,
and what was normal:
12

“I just think, for me the chemo’s given me this neuropathy and I mean I’m learning to walk
again, and stuff like that, I can’t feel my legs so it’s like I’m on air cushions…” F_46yo_NHL

For some, the changes post-treatment were noticed when trying to get back to exercise
and movement. They felt their physical abilities had declined:
“Yeah, I mean I walk the streets but I don’t like doing that, I can go one block and then I’m
exhausted. But I do feel better when I do something, but I can’t do it long enough for it to
benefit me.” F_75yo_NHL

Many participants spoke about coping with the emotional experience and impact
of their cancer treatment through avoidance:
“I can personally say that I did have my down moments … but it’s so hard and I thought it’s
worse being in this state, just get out- just get going, just don’t think about it – it’s easier to
just get on with it rather than get depressed – I know that’s easier said than done.”
F_28yo_NHL

Living with the fear of cancer recurrence was described as a common experience
and although one or two participants talked about seeking help and reassurance to
address their fear, most described getting on with living alongside the uncertainty and
fear:
“I don’t think you ever quite get rid of the shadow … I don’t think you ever get free of that
slightly depressed feeling that’s in the back of your head that it could come back.”
F_46yo_NHL
“I just want to be living well. ...if I’m going to live for only 5 more years, I just want to live
well for those 5 years and extract as much as I can…” M_48yo_HL
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The most commonly mentioned strategies used post-treatment to try and cope
with the impact of their diagnosis, its treatment and on-going uncertainty included
exercise, having children around, and hope for the future:
“[Weight lifting exercise class] I went twice a week and after 3 months I was really feeling
much better and almost back to my energy level and I’m not even back to it now after a
year, and that was a twice a week thing which was really good. So then I thought if I can go
to weight lifting I can go to badminton, and I did that twice a week and that kept my mind
occupied, something to do and being active and I think it is something that’s very useful.”
F_46yo_NHL
“I think having kids around brings you up a bit and makes you realise that life isn’t so
tough…” F_28yo_NHL
“…but also you need to be busy mentally and do things for the future and I really amazed
myself in two months after chemo when I planted my vegetables and I thought ‘will I be
alive to eat it’.” F_46yo_NHL

Family and significant others, support and post-treatment experience
Family members and significant others were largely seen as helpful but at times
participants described experiences where they could be unintentionally dismissive and
appeared to lack understanding:
“… people say to me, think positive. What does that mean? You know what I mean? I
understand the concept of it…” M_48yo_HL
“… you’re back doing the dishes, doing the washing, where as everyone kind of rallied
before, yep you’re alright now – off you go.” F_52yo_NHL
“I’ve got young children, you know, - so you still are carrying on with your parental duties and
all of that sort of stuff, but as soon as you’ve got your remission … certain people in my life
went – oh he’s fixed, and suddenly you’re not cancer boy any more so people suddenly
switch off …” M_48yo_HL

Some participants commented that as they physically and outwardly began to
look better, others’ expectations of them changed:
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“But when your hair grows again and your skin colour comes back and you’re not passed
out in the chair most of the time, … people tend to quickly move on from that where as you
haven’t you know what I mean, you haven’t’. … whilst you’re not having chemo any more
it’s not finished for you yet…” M_48yo_HL

Some participants had found value in attending peer support groups where others
understood what they had gone through and experienced:
“It’s just like everybody’s been saying, it’s nice to come where people understand you – I
mean that my family and friends have all been amazing but they don’t understand. They just
all say yes we know you’re going through it and we feel for you, but they just don’t
understand.” F_46yo_NHL

One participant found the support received from belonging to a group of other young
people made a big difference to their experience:
“… I couldn’t kind of get along with the people I was having treatment with just because our
lives were so different. It was so helpful … I just went to those little meetings and there
were people my age talking about the same sort of stuff.” F_28yo_NHL

But for others a group situation was difficult, at times overwhelming, leaving them
feeling uncomfortable:
“You’re always identified as the cancer person or with the cancer group … but sometimes it
weighs a bit heavy, like the people there you don’t necessarily want to broadcast it to the
whole world.” F_75yo_NHL

Transition, connectivity and normalcy
The relationships established during treatment and the security that came
through knowing they were being treated and monitored closely by an expert or team
who genuinely cared for them was greatly valued:
“I just had this feeling of ‘wow’ I am so privileged to have the treatment and the knowledge of
the professional care here, the medical staff, all of them …” F_73yo_NHL
15

“I was under Dr X and they always said that you know, if you ever have any problems, ring
me personally and you can come straight in, don’t bat an eyelid. So I was very confident in
the team and I knew there was support if I needed it.” F_52yo_NHL

But with completion of treatment and the transition to a different relationship with
the hospital and treating team, some participants felt that although their medical needs
were met, they did not feel connected or understood holistically:
“… my specialist is great, … excellent doctor, but I walk in there and you get nothing other
than your um, medical moment for want of a better term- there’s no, you know, like [the
doctor’s] just happy that you’ve got a remission so [the doctor’s] done the job, you know,
and it was literally, ok ‘so what happens now?’ ‘I’ll see you in 3 months.’” M_48yo_HL

Leaving the support of the hospital was experienced as a loss. Some felt their safety net
and reassurance had gone along with the camaraderie of other patients who were
undergoing a similar experience. Many were left wondering what their purpose was
moving forward:
“I used to be this guy that had a sense of purpose and a reason for going– all of a sudden
all of that is taken away and no-one’s telling you what to do next, it’s just come and see me
in 3 months’ time… for me, a massive sense of loss. It’s a loss of purpose and identity,
actually. … You know I used to call them my chemo buddies and yeah you’d sit with the
same people every time and the nurses, everybody that you just had a connection with and
it’s just severed.” M_48yo_HL

Participants spoke about being so focused on getting through treatment they had
not had time to process what would happen when treatment finished. There was a
sense of adjusting to this change post-treatment without adequate preparation. One
participant talked about having to take responsibility for herself again:
“… but I felt um hang on, they’ve spewed me out the door and I thought; now I’m going to
have to do something for myself.” F_46yo_NHL
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Overwhelmingly, participants wanted things to return to normal or a new normal
post-treatment. They wanted to get on to with their lives, get back to work and move
forward; to put cancer to one side or leave it behind:
“… and I got to a point after treatment where I just told my friends to stop talking about it
and stop asking I felt like it was taking over my life and I wanted other things to focus on.”
F_28yo_NHL

But moving from the structure of treatment and hospital support back into “normal
life” was difficult. Some expected to return to their life as it was pre-diagnosis and found
it challenging when this did not happen:
“… when your chemo’s finished they kept telling me it would take a year to get back to
normal and I’m like ‘you don’t know me, that’s not going to happen, I’m going to walk out of
here and flip a switch and I’m going to be back to normal’ well it’s not the case.”
M_51yo_NHL

The need to find a new meaning or purpose post-treatment and a realisation that
one had changed and that what matters in life had changed were strong elements in the
data gathered:
“You lose kind of like your purpose in life, you’re not the same like you used to be before
your cancer.” F_46yo_NHL
“You’re not so cocky now, … I really have sympathy for others, whereas before – now I
really listen to them.” M_66yo_NHL
“I never want to be a CEO again, I never want to be in that place, I want to be there for me
and my family… it certainly makes you more empathetic- makes you have more empathy
for others, it certainly gives you that gene, because I certainly didn’t have much at all
[before].” M_48yo_HL

Moving away from the “cancer label” and not wanting to be stigmatised was
important for many participants as they transitioned into the post-treatment phase:
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“When I went to the gym with the cancer group … I would have really benefitted from
having an individual membership and being by myself ... you get a card and ‘oh, are you
with the cancer group?!’ I don’t want to be labelled all the time … even though you’re
looking for support.” F_52yo_NHL

Person centred post-treatment care
Participants recognised that support needs varied from diagnosis through
treatment and on into follow-up, the post-treatment stage. But when discussion was
guided during the focus groups to services or support that would have been useful posttreatment, participants talked about the need for this to be individualised, stating it
would be difficult to get a “one size fits all” approach to their support needs:
“A group is great. But if you were ringing up asking for help you’d probably want one-onone.” M_70yo_NHL

However, most participants felt that some sort of “check-up” (follow-up) appointment at
the hospital around one month post-treatment would be helpful where the focus was on
the experience of the individual rather than the disease:
“I think a follow-up would be a good idea because there aren’t any follow-ups as such. A
formal follow-up, either with a clinical psychologist or nurse when you come for your cancer
follow-ups.” F_70_NHL

Some participants suggested this appointment should be mandatory, a logical transition
from hospital care to a “new normal”:
“I also don’t think that if you make someone available it will do any good. You got to send
me there. You’ve got to have an appointment for me to go there otherwise I’ll use tomorrow
[as an excuse not to go].” M_70yo_NHL

Wanting a personal connection with a qualified professional was a strong theme,
a person to seek reassurance from and check worrying symptomology:
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“When you can phone somebody who is there for you right then and there specifically for
that reason, to say well if you’re worried, yes go and see - because you doubt yourself, you
think am I being neurotic about every little ache or pain … am I being silly or should I see
the doctor, maybe I’m just being silly. It would just be nice to have that support that you
know that there’s the cancer nurse there for you, somebody in the know that can say ‘don’t
worry about it’ or ‘yes come in and see your specialist.” F_46yo_NHL

Peer support was also described as valuable when the peer had undergone a similar
experience and for some people it was important to get away from “the medics”:
“…probably the best thing that could happen to those other people is not go and see the
specialist, but sit in a room with us.” M_48yo_HL
“…I would have appreciated a formal session like this, talking to people who’ve already
been where I was and where I’m going.” M_51yo_NHL

DISCUSSION
This research contributes to a small but growing body of literature reporting on
post-treatment experiences and support needs of survivors of lymphoma. Data from our
study identified five key themes of relevance to the post-treatment experience of
lymphoma survivors: Information; Loss and uncertainty; Family, support and posttreatment experience; Transition, connectivity and normalcy, and Person-centred posttreatment care.
Information needs varied across participants in our study, reflecting findings from
other qualitative studies of haematological cancer survivors (Gansler et al., 2010) and
emphasising the importance of flexibility in services developed if they are to
successfully address the information needs of post-treatment survivors. Participants in
this study described difficulty in accessing the kind of information they needed from
tertiary and community health professionals once the acute treatment period was over,
a finding commonly reported in studies of non-haematology cancer survivors (Taylor
19

and Monterosso, 2016). Participants described a sense of loss in terms of support,
connectivity and reassurance when they transitioned away from active care to the posttreatment phase, indicating that there is opportunity to develop and implement tailored
post-treatment preparation interventions to enhance the experience and wellbeing of
haematology survivors. Living with fear of cancer recurrence was a common experience
for participants in our study, and is widely recognised as one of the most distressing or
prevalent concerns of cancer survivors (Butow et al., 2015; Park et al., 2013). Helping
people find strategies to live with fear of recurrence is a key issue in the advancement
of post-treatment survivorship care.
Dealing with the side effects of treatment was described as one of the most
difficult aspects of the post-treatment phase. Participants in our study felt they weren’t
adequately prepared to manage the issues they faced, and suggested that information
on the duration of side effects, what to expect and how to cope with them would have
been helpful. This finding offers an important and achievable target for improvement in
post-treatment care of survivors of lymphoma.
Some participants described difficulty in adjusting to a “new normal” posttreatment and actively sought a new sense of purpose and identity. A clear sense of
moving away from cancer and putting it to one side so that a new norm could be
established was evident for some. This finding suggests that working with patients
ahead of treatment completion to prepare a “new narrative” for themselves may better
support people to transition from their identity as a cancer patient.
Although there was a general recognition of the value of support provided
through existing family and friend networks, some participants felt that once they started
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to look and feel better, family or significant others’ expectations of what they were
capable of doing exceeded what they felt ready or able to do. The need to develop
survivorship services that directly support families or important others so they can be
effective partners in the transition to life post-treatment, as well as keep themselves
well, is evident.
In response to questions about helpful components of post-treatment care, many
participants described the ability to contact a health professional to seek reassurance,
check in about concerning symptoms and get advice and information as an important
element in enabling confident transition to survivorship. Specialist post-treatment nurse
care coordinators working across tertiary and community settings may offer an effective
model to address this need for survivors of haematological malignancies.
A follow-up appointment post-treatment focusing on refection of the diagnosis
and treatment experience as a way of being able to “move on” to the next phase of life
was also recommended as a potentially useful intervention and is worthy of
consideration as one component of person-centred post-treatment care.

Limitations
The limitations in this study include the small sample size and the single site
recruitment. However, the findings do offer valuable insight into the post-treatment
experiences and support needs of participants in our study, and offer tangible
opportunity for the development of post-treatment services and interventions targeted to
the needs of survivors of lymphoma, although more works needs to be done to establish
the credibility of our findings to other haematological cancer patients’ post-treatment.
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Participants chose to opt-in and therefore it is not possible to assess whether those with
greater needs or worse experiences of post-treatment care excluded themselves.
However, experiences of those people who gave their time to take part have provided a
valuable addition to a small but growing body of research in this area. The use of a
clinical psychologist as the facilitator for the focus groups (disclosed to participants at
the beginning of the focus group) may have influenced the issues participants chose to
share or withhold dependent on previous access to or attitudes toward a psychologist.

CONCLUSION
Survivors of lymphoma experience many and complex post-treatment issues that
require tailored intervention as part of a comprehensive package of person-centred
post-treatment care. Data from our study suggest that integration of professional, peer
and family/important other support strategies may prove to be most effective. Specialist
haematology nurse care coordinators working across tertiary and community settings
could offer a feasible and efficient way of coordinating tailored programs of support
around survivors of haematological malignancies.
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